ZA202310905B - Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same - Google Patents
Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the sameInfo
- Publication number
- ZA202310905B ZA202310905B ZA2023/10905A ZA202310905A ZA202310905B ZA 202310905 B ZA202310905 B ZA 202310905B ZA 2023/10905 A ZA2023/10905 A ZA 2023/10905A ZA 202310905 A ZA202310905 A ZA 202310905A ZA 202310905 B ZA202310905 B ZA 202310905B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- same
- herpes virus
- adenoviral vectors
- vectors encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958827P | 2020-01-09 | 2020-01-09 | |
| US202062958809P | 2020-01-09 | 2020-01-09 | |
| US202062967104P | 2020-01-29 | 2020-01-29 | |
| US202062967242P | 2020-01-29 | 2020-01-29 | |
| US202063064506P | 2020-08-12 | 2020-08-12 | |
| US202063064571P | 2020-08-12 | 2020-08-12 | |
| US202063112219P | 2020-11-11 | 2020-11-11 | |
| US202063112202P | 2020-11-11 | 2020-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202310905B true ZA202310905B (en) | 2025-06-25 |
Family
ID=74505354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/10905A ZA202310905B (en) | 2020-01-09 | 2023-11-27 | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US12605444B2 (https=) |
| EP (1) | EP4087605A1 (https=) |
| JP (2) | JP7696909B2 (https=) |
| KR (1) | KR20220163354A (https=) |
| CN (2) | CN115335076B (https=) |
| AU (1) | AU2021205936A1 (https=) |
| BR (1) | BR112022013620A2 (https=) |
| CA (1) | CA3166989A1 (https=) |
| IL (1) | IL294387A (https=) |
| MX (1) | MX2022008572A (https=) |
| PH (1) | PH12022551648A1 (https=) |
| WO (1) | WO2021142212A1 (https=) |
| ZA (1) | ZA202310905B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294387A (en) * | 2020-01-09 | 2022-08-01 | Virion Therapeutics Llc | Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054262A1 (en) | 2003-03-28 | 2007-03-08 | Baker Denise M | Methods of identifying optimal variants of peptide epitopes |
| US20090246220A1 (en) * | 2006-08-28 | 2009-10-01 | Ertl Hildegund C J | Constructs for enhancing immune responses |
| EA028659B1 (ru) * | 2011-02-12 | 2017-12-29 | Глоубиммьюн, Инк. | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| EP2959915A1 (en) * | 2014-06-23 | 2015-12-30 | Institut Pasteur | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection |
| CN105367662B (zh) * | 2014-08-29 | 2021-03-12 | 汤正好 | 一种hbv相关的融合蛋白、其制备方法及其应用 |
| US11324819B2 (en) | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
| SG11201900808SA (en) | 2016-08-01 | 2019-02-27 | Wistar Inst | Compositions and methods of replication deficient adenoviral vectors for vaccine applications |
| CN119770638A (zh) * | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| IL294387A (en) * | 2020-01-09 | 2022-08-01 | Virion Therapeutics Llc | Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them |
-
2021
- 2021-01-08 IL IL294387A patent/IL294387A/en unknown
- 2021-01-08 CN CN202180019813.3A patent/CN115335076B/zh active Active
- 2021-01-08 KR KR1020227027069A patent/KR20220163354A/ko active Pending
- 2021-01-08 JP JP2022542413A patent/JP7696909B2/ja active Active
- 2021-01-08 CA CA3166989A patent/CA3166989A1/en active Pending
- 2021-01-08 AU AU2021205936A patent/AU2021205936A1/en active Pending
- 2021-01-08 MX MX2022008572A patent/MX2022008572A/es unknown
- 2021-01-08 PH PH1/2022/551648A patent/PH12022551648A1/en unknown
- 2021-01-08 WO PCT/US2021/012630 patent/WO2021142212A1/en not_active Ceased
- 2021-01-08 EP EP21703111.1A patent/EP4087605A1/en active Pending
- 2021-01-08 BR BR112022013620A patent/BR112022013620A2/pt unknown
- 2021-01-08 US US17/790,259 patent/US12605444B2/en active Active
- 2021-01-08 CN CN202511456350.3A patent/CN121221754A/zh active Pending
- 2021-08-27 US US17/459,313 patent/US11291716B2/en active Active
-
2022
- 2022-02-24 US US17/679,356 patent/US11850282B2/en active Active
-
2023
- 2023-10-24 US US18/492,945 patent/US12290561B2/en active Active
- 2023-11-27 ZA ZA2023/10905A patent/ZA202310905B/en unknown
-
2025
- 2025-04-04 US US19/170,785 patent/US20250228934A1/en active Pending
- 2025-06-11 JP JP2025097871A patent/JP2025124904A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220163354A (ko) | 2022-12-09 |
| JP2025124904A (ja) | 2025-08-26 |
| US12605444B2 (en) | 2026-04-21 |
| CN121221754A (zh) | 2025-12-30 |
| CN115335076B (zh) | 2025-10-28 |
| JP7696909B2 (ja) | 2025-06-23 |
| IL294387A (en) | 2022-08-01 |
| JP2023510544A (ja) | 2023-03-14 |
| CA3166989A1 (en) | 2021-07-15 |
| US20220175913A1 (en) | 2022-06-09 |
| US11291716B2 (en) | 2022-04-05 |
| BR112022013620A2 (pt) | 2022-09-13 |
| US11850282B2 (en) | 2023-12-26 |
| US20240091347A1 (en) | 2024-03-21 |
| US20250228934A1 (en) | 2025-07-17 |
| EP4087605A1 (en) | 2022-11-16 |
| US20230063089A1 (en) | 2023-03-02 |
| CN115335076A (zh) | 2022-11-11 |
| US12290561B2 (en) | 2025-05-06 |
| WO2021142212A1 (en) | 2021-07-15 |
| PH12022551648A1 (en) | 2024-02-12 |
| MX2022008572A (es) | 2022-09-23 |
| AU2021205936A1 (en) | 2022-07-21 |
| US20210393770A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107921115B (zh) | 新颖杆状病毒载体及使用方法 | |
| AU2019349036A8 (en) | Immune composition, preparation method therefor, and application thereof | |
| ECSP064643A (es) | Proteinas de fusion de glp-1 | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| ZA8997B (en) | Recombinant vaccinia virus mva | |
| PL338478A1 (en) | Immunological response in respect to hpv antigens induced by compositions comprising a hpv antigen and a shock protein or expression vector capable to express such protein | |
| WO2011138251A8 (en) | Lentiviral vector based immunological compounds against malaria | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| RU2015135890A (ru) | Композиция вакцины | |
| MX2024004293A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| ZA202310905B (en) | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same | |
| PH12021550898A1 (en) | Virus-like particles of cmv modified by fusion | |
| ZA202203974B (en) | Canine distemper virus hemagglutinin and fusion polypeptides | |
| WO2021239838A3 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
| WO2007053188A3 (en) | Production of multivalent virus like particles | |
| RU2017132190A (ru) | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними | |
| TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
| PH12018502430A1 (en) | Vaccines | |
| DE60236579D1 (de) | Bakteriophagenvermittelte impfung | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| WO2001049712A3 (en) | Vaccine against isav (infectious salmon anaemia virus) | |
| WO2002038769A3 (de) | Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen | |
| AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes | |
| BR112023020640A2 (pt) | Partículas similares a vírus de bacteriófago ap205 modificadas | |
| WO2004032622A3 (en) | Production of peptides in plants as viral coat protein fusions |